Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 79.78

0.0%

Dec 31 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (2953)	6/18/2010 8:56:13 AM
From: Jibacoa	1 Recommendation of 3722

After finding support at the $45 level, NVS has continued to move up without closing UGs.<g> It had a strong close yesterday and today should have no problem on going through the resistance at the $40 level.<g> bigcharts.marketwatch.com NVS announced that the FDA has approved Tasigna (nilotinib) 150 mg capsules for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive CML. Tasigna is now the first new therapeutic option for newly diagnosed patients since the introduction of Gleevec tablets. NVS has 2Qs of better revenues and earnings. In April it started the 2nd PI for PTH1-34 for treatment of postmenopausal osteoporosis. The LTD is moderate. It has good *CF and the Y around 3% isn't bad these days.<g> The ACTAY is $65.43 That could be doable, although there is a good amount of resistance at the $55 level.<g> bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next